Download Free Handbook Of Chronic Myeloid Leukemia Book in PDF and EPUB Free Download. You can read online Handbook Of Chronic Myeloid Leukemia and write the review.

This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1–2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria.
Highly Commended, BMA Medical Book Awards 2014 Chronic myeloid leukemia is a clonal disease that results from an acquired genetic change in a single pluripotential hemopoietic stem cell. Efforts to confront this disease have been assisted by advances in cellular and molecular biology and the speed at which these findings have transformed the therapeutic algorithm. Nevertheless, there is some uncertainty with regards to how best to assess efficacy of treatment, especially with regards to the most appropriate surrogate markers for overall survival. From the standpoint of biology and clinical management, this handbook provides an authoritative state-of-the-art review of current and developing progress.
This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML. Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.
Chronic Myeloid Leukemia: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Genetics. The editors have built Chronic Myeloid Leukemia: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Genetics in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Chronic Myeloid Leukemia: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
This book provides an overview of the key developments in both acute lymphocytic leukemia and acute myeloid leukemia with a comprehensive guide to the epidemiology, pathogenesis, etiology, clinical manifestations, classification, diagnosis, and staging as well as the most recent developments in the therapeutic landscape for acute leukemia. The Handbook of Acute Leukemia offers readers a key resource into the future outlook for patients with leukemia and is edited and authored by internationally renowned experts in the field. Leukemia is cancer of the white blood cells and acute leukemia means the condition progresses rapidly and aggressively, requiring immediate treatment. Acute leukemia is classified according to the type of white blood cells that are affected: either lymphocytes and myeloid cells.
Chronic Myeloid Leukemia: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Chronic Myeloid Leukemia. The editors have built Chronic Myeloid Leukemia: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Chronic Myeloid Leukemia in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Chronic Myeloid Leukemia: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Targeted therapy has revolutionised modern oncology practice and has completely changed the outcome of once universally fatal diseases like chronic myeloid leukaemia (CML). The last decade has witnessed significant advances in the management of CML, which has become more like a chronic disease. Written by experts in the field, this volume nicely describes the current knowledge of the pathophysiology, clinical features, and management of CML. It covers not only clinical topics but also the basic science underlying these practices. It will be of help to clinicians and basic scientists alike. In addition to the state of the art treatment of CML, this book also covers many uncommon but very important special topics like management of CML in pregnancy or with children, management of resistance to new tyrosine kinases and treatment of the advanced phase of the disease. Written to be easily digestible, patients will also be able to access important and universally useful information on CML (eg: diagnosis, symptoms and signs, and treatment). Some themes especially, including drug and food interactions of tyrosine kinase inhibitors (TKIs), CML treatment during pregnancy, advantages/disadvantages of the most commonly used TKIs, and bone marrow transplantation indications, will be of popular concern. This extensively referenced book therefore should be of great help to both novices and experts in the field.
Our understanding of myeloproliferative neoplasms (MPN) disorders has grown considerably over the past four decades. Myeloproliferative Neoplasms offers a detailed evidence-based guide to MPNs in an easily accessible format, structure to facilitate learning specialist information presenting core information in 'bite size' chunks.